학술논문
Comparison of Clinical Efficacy of Rokitamycin (RKM) and Ofloxacin (OFLX) for the Treatment of Campylobacter Enteritis by a Double-Blind Method / カンピロバクター腸炎に対するRokitamycin (RKM, TMS-19-Q) とOfloxacinの二重盲検比較試験
Document Type
Journal Article
Author
Akira FUKUMOTO; Akira MACHII; Akira MURAMOTO; Atsushi AJISAWA; Chie NAKAMURA; Fukiko AMANO; Fumio MATSUMOTO; Gohta MASUDA; Hideyuki KANOU; Hiroko SAGARA; Isao TOMIZAWA; Iwao MATSUSHITA; Iwao SAKURAI; Jun NARUSE; Junichi SATO; Katsuyuki KITOH; Kazuya TAMURA; Keiko LEE; Kenichi TATEWAKI; Kenji FUSE; Kenji OHNISHI; Kuniko KURISU; Kunio YOSHIKAWA; Makoto SAITO; Masami MURAI; Masao NAKAGAWA; Masaya SASAKI; Masayoshi NEGISHI; Michio TANAKA; Minoru KIZU; Misako MURATA; Mitsuo KITAHARA; Mitsuo OBANA; Mitsuru AKAO; Osamu KURIMURA; Rintaro NAKAYA; Sadao KATAOKA; Sankichi HORIUCHI; Satomi OTA; Shiro HOSODA; Shoichiro IRIMAJIRI; Tadao BAMBA; Takafumi TSUNODA; Takayuki TAKAHASHI; Takehiko SHIOMI; Takehisa SEO; Takeo IMAI; Teiko KATANO; Toshio KAWAJIRI; Tsuyoshi YAMAGUCHI; Yasuhiko INAMOTO; Yasuo MATSUOKA; Yatsuka IMAGAWA; Yong-ki KIM; Yoshihiko TAKIZAWA; Yoshihiro SAKAUE; Yoshio INAGAKI; Yoshio KAWAGUCHI; Yoshio MATSUBARA; Yoshiro NITTA; Yoshitaka NAKAMURA; リー 啓子; 中川 雅夫; 中村 千衣; 中村 嘉孝; 中谷 林太郎; 今井 健郎; 今川 八束; 佐々木 雅也; 佐藤 純一; 入交 昭一郎; 冨澤 功; 加納 英行; 北原 光夫; 吉川 邦生; 味沢 篤; 堀内 三吉; 塩見 毅彦; 増田 剛太; 大田 聡美; 大西 健児; 天野 冨貴子; 小花 光夫; 山口 剛; 川口 義夫; 川尻 敏夫; 布施 建治; 成瀬 順; 新田 義朗; 木津 稔; 木藤 克之; 村井 雅巳; 村元 章; 村田 三紗子; 松下 巌; 松原 義雄; 松岡 康夫; 松本 文夫; 栗村 統; 栗須 久仁子; 根岸 昌功; 桜井 磐; 滝沢 慶彦; 瀬尾 威久; 片岡 定男; 片野 てい子; 田中 美智男; 田村 和也; 町井 彰; 相楽 裕子; 福本 晃; 稲垣 好雄; 稲本 康彦; 立脇 憲一; 細田 四郎; 角田 隆文; 赤尾 満; 金 龍起; 阪上 賀洋; 馬場 忠雄; 高橋 孝行; 齋藤 誠
Source
感染症学雑誌 / Kansenshogaku Zasshi. 1991, 65(9):1165
Subject
Language
Japanese
ISSN
0387-5911
1884-569X
1884-569X
Abstract
The clinical efficacy, safety and usefulness of Rokitamycin (RKM), a new macrolide antibiotic, were compared with those of Ofloxacin (OFLX) for the treatment of Campylobacter enteritis by a double blind method.The daily dose level of RKM or OFLX was 600 mg. They were orally administered in three divided doses for 5 days.Of 223 cases studied, 106 cases were diagnosed as Campylobacter enteritis. Ninety cases (RKM group: 50, OFLX group: 40) except for 16 excluded or drop-out cases were analysed. There was no significant difference between the two groups in any background factors. The effectiveness and usefulness was evaluated in 88 cases (RKM group: 48, OFLX group: 40).The results obtained were as follows:1. In a total of 82 strains of Campylobacter jejuni/coli (RKM group: 42, OFLX group: 40), the bacteriological efficacy rate of RKM (95.2%) was superior to that of OFLX (70.0%) with a significant difference (p=0.006).2. In 76 symptomatic patients (RKM group: 42, OFLX group: 34) on the day of the beginning of drug administration, the clinical efficacy rate was 97.6% in the RKM group and 85.3% in the OFLX group with no significant difference between the two groups.3. In 88 evaluable patients, the global clinical efficacy rate of RKM (95.8%) was superior to that of OFLX (67.5%) with a significant difference (p=0.001).4. Side effect was observed in 1 (1.9%) of the 54 patients in the RKM group and none of the 44 patients in the OFLX group. Slightly abnormal laboratory findings were seen in 4 (10.8%) of the 37 patients treated with RKM and 3 (9.7%) of the 31 patients treated with OFLX, but there was no significant difference between the two groups.5. In 88 evaluable patients, the clinical usefulness of RKM (91.7%) was superior to that of OFLX (67.5%) with a significant difference (p=0.01).From these results, RKM is considered to be a very useful agent for the treatment of Campylobacter enteritis.